Stopping weight loss jabs can lead to rapid weight regain in one year, study suggests
New Study Indicates Weight Loss Jabs May Result in Quick Weight Regain After Discontinuation
A recent investigation reveals that individuals utilizing weight loss injections for obesity could regain most of their lost weight within a year of stopping the medication, according to preliminary findings.
Cambridge Research Highlights Weight Regain Trends
Researchers at the University of Cambridge observed that, after 52 weeks without treatment, participants on average recovered 60% of the weight they had previously lost. This suggests a significant return to pre-treatment levels, raising concerns about long-term effectiveness.
Experts caution that if the regained mass is predominantly fat, patients might face worse health outcomes compared to before starting the therapy. The study underscores the need for understanding how weight composition changes post-treatment.
“Our projections show that even though people regain most of the weight they have lost, they still maintain some of the weight loss, but what we currently don’t know is if the same proportion of lean mass is recovered,” said Brajan Budini, a medical student at the University of Cambridge.
Further analysis indicates that weight regain may stabilize, with 75% of initial loss recovered by 60 weeks. This implies that 25% of the weight reduction could be sustained over time, though the exact impact on lean mass remains unclear.
GLP-1 Receptor Agonists: Mechanism and Applications
Weight loss jabs are a category of medications called GLP-1 receptor agonists, which replicate the hormone GLP-1 to manage blood sugar and insulin. Initially developed for type 2 diabetes, certain variants like semaglutide and tirzepatide are now used on the NHS for obesity treatment.
A separate study involving over 600,000 U.S. veterans with diabetes found that these jabs also help prevent substance use, including addiction to alcohol, tobacco, and narcotics. The research, published in the British Medical Journal, showed reduced risks for various substances.
The findings revealed a 14% lower likelihood of developing substance use disorders in non-addicted veterans, alongside notable decreases in misuse rates for alcohol, cannabis, cocaine, nicotine, and opioids. For those already struggling with addiction, the jabs were linked to a 31% reduction in emergency visits, hospitalizations, and overdose incidents.
Despite focusing on older male veterans, the study found similar effects in female participants, broadening its relevance across demographics.
Call for Further Exploration of Weight Composition
Researchers urged more trials to assess how these drugs influence weight composition during and after use. Understanding whether lean mass is preserved could determine the long-term health benefits of the treatment.
